Imunon (NASDAQ:IMNN) Upgraded by EF Hutton Acquisition Co. I to “Strong-Buy”

EF Hutton Acquisition Co. I upgraded shares of Imunon (NASDAQ:IMNN) to a strong-buy rating in a research note issued to investors on Monday morning, Zacks.com reports.

Separately, HC Wainwright restated a buy rating and set a $14.00 price target on shares of Imunon in a research note on Thursday, August 15th.

Imunon Price Performance

Imunon stock opened at $1.03 on Monday. Imunon has a twelve month low of $0.48 and a twelve month high of $3.65. The firm has a 50 day moving average price of $1.20 and a 200-day moving average price of $1.26. The company has a market capitalization of $61.85 million, a P/E ratio of -0.51 and a beta of 2.13.

Imunon (NASDAQ:IMNN) last released its earnings results on Wednesday, August 14th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.04. Equities analysts expect that Imunon will post -1.71 EPS for the current fiscal year.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.